Literature DB >> 16886590

Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Emily von Scheven1, Catherine M Gordon, David Wypij, Marcia Wertz, Kerry T Gallagher, Laura Bachrach.   

Abstract

OBJECTIVE: To evaluate the relationship between chronic glucocorticoid (GC) exposure and bone mineral density (BMD) in children with rheumatic diseases and inflammatory bowel disease. STUDY
DESIGN: Lumbar spine BMD was measured by DXA in 86 GC-treated children (66% female, age 8-20 years, mixed ethnicity) screened for a multi-center intervention trial. Predictors of spine BMD z-score and vitamin D [25(OH)D] were examined by multivariable linear regression.
RESULTS: Mean prior year and lifetime cumulative GC exposure was 77.8 mg/kg and 224.6 mg/kg, respectively. BMD z-scores ranged from -3.7 to 2.2 SD (-1.1 +/- 1.2, mean +/- SD). Lower BMD z-scores were associated with increased prior year average daily GC dose (p = 0.03), decreased height z-score (p = 0.003), and decreased 25(OH)D concentrations (p = 0.03), but explained only a small proportion of BMD variability (adjusted R2 = 0.29). The 25(OH)D levels were <20 ng/ml in 45% of patients, and low 25(OH)D was associated with non-Caucasian ethnicity (p <0.001), increased age (p = 0.004), increased parathyroid hormone (p = 0.03), and residing in the Boston area (p <0.001).
CONCLUSIONS: Although GC exposure is significantly associated with BMD z-score, the association is too variable to serve as a consistent predictor of reduced BMD in children. Vitamin D insufficiency is common and may contribute to skeletal deficits in this population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16886590      PMCID: PMC3899936          DOI: 10.1515/jpem.2006.19.6.821

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  26 in total

Review 1.  A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

Authors:  R Eastell; D M Reid; J Compston; C Cooper; I Fogelman; R M Francis; D J Hosking; D W Purdie; S H Ralston; J Reeve; R G Russell; J C Stevenson; D J Torgerson
Journal:  J Intern Med       Date:  1998-10       Impact factor: 8.989

2.  Evaluation of low density spine software for the assessment of bone mineral density in children.

Authors:  M B Leonard; H I Feldman; B S Zemel; J A Berlin; E M Barden; V A Stallings
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

Review 3.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

4.  Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise.

Authors:  Khayriah A Alsufyani; Olivia Ortiz-Alvarez; David A Cabral; Lori B Tucker; Ross E Petty; Helen Nadel; Peter N Malleson
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

5.  Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III.

Authors:  Anne C Looker; B Dawson-Hughes; M S Calvo; E W Gunter; N R Sahyoun
Journal:  Bone       Date:  2002-05       Impact factor: 4.398

6.  Bone mineral density of Brazilian girls with juvenile dermatomyositis.

Authors:  T C M de Castro; M T R A Terreri; V L Szejnfeld; C Len; A S M da Fonseca; M O E Hilário
Journal:  Braz J Med Biol Res       Date:  2005-02-15       Impact factor: 2.590

7.  Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.

Authors:  Carolina Di Somma; Rosario Pivonello; Sandro Loche; Antongiulio Faggiano; Michele Klain; Marco Salvatore; Gaetano Lombardi; Annamaria Colao
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

8.  A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis.

Authors:  Gunhild Lien; Anne M Selvaag; Berit Flatø; Margaretha Haugen; Odd Vinje; Dag Sørskaar; Knut Dale; Thore Egeland; Øystein Førre
Journal:  Arthritis Rheum       Date:  2005-03

9.  Children and the risk of fractures caused by oral corticosteroids.

Authors:  T P van Staa; C Cooper; H G M Leufkens; N Bishop
Journal:  J Bone Miner Res       Date:  2003-05       Impact factor: 6.741

10.  Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density.

Authors:  S Trapani; R Civinini; M Ermini; E Paci; F Falcini
Journal:  Rheumatol Int       Date:  1998       Impact factor: 2.631

View more
  11 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 2.  Exercise and inflammatory bowel disease.

Authors:  Neeraj Narula; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2008-05       Impact factor: 3.522

Review 3.  Drug interventions for the treatment of obesity in children and adolescents.

Authors:  Emma Mead; Greg Atkinson; Bernd Richter; Maria-Inti Metzendorf; Louise Baur; Nicholas Finer; Eva Corpeleijn; Claire O'Malley; Louisa J Ells
Journal:  Cochrane Database Syst Rev       Date:  2016-11-29

4.  Vitamin D deficiency in children with inflammatory bowel disease.

Authors:  Alon D Levin; Veena Wadhera; Steven T Leach; Helen J Woodhead; Daniel A Lemberg; A Czarina Mendoza-Cruz; Andrew S Day
Journal:  Dig Dis Sci       Date:  2011-01-11       Impact factor: 3.199

5.  Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up.

Authors:  Darrell M Wilson; Stephanie H Abrams; Tandy Aye; Phillip D K Lee; Carine Lenders; Robert H Lustig; Stavroula V Osganian; Henry A Feldman
Journal:  Arch Pediatr Adolesc Med       Date:  2010-02

Review 6.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

Review 7.  Pediatric bone density and fracture.

Authors:  Emily von Scheven
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

8.  Relation of body fat indexes to vitamin D status and deficiency among obese adolescents.

Authors:  Carine M Lenders; Henry A Feldman; Emily Von Scheven; Anne Merewood; Carol Sweeney; Darrell M Wilson; Phillip D K Lee; Stephanie H Abrams; Stephen E Gitelman; Marcia S Wertz; William J Klish; George A Taylor; Tai C Chen; Michael F Holick
Journal:  Am J Clin Nutr       Date:  2009-07-29       Impact factor: 7.045

Review 9.  Vitamin D status in gastrointestinal and liver disease.

Authors:  Helen M Pappa; Elana Bern; Daniel Kamin; Richard J Grand
Journal:  Curr Opin Gastroenterol       Date:  2008-03       Impact factor: 3.287

Review 10.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.